Comparative Pharmacology
Head-to-head clinical analysis: CLADRIBINE versus JYLAMVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLADRIBINE versus JYLAMVO.
CLADRIBINE vs JYLAMVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
None Documented
None Documented
Clinical Note
moderateCladribine + Digoxin
"Cladribine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCladribine + Digitoxin
"Cladribine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCladribine + Deslanoside
"Cladribine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCladribine + Acetyldigitoxin
"Cladribine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent